PharmTech Drug Digest 11.20
News|Articles|October 8, 2013

Marken Announces Depot in Russia; Makes Senior Appointment

Marken announces a new depot in Russia and makes a senior appointment.

Marken, a provider of clinical-trial material supply solutions, has added a depot in Moscow as part of its global pharmaceutical depot network. The Russian depot will be located within an existing GxP-compliant storage facility in Moscow. The facility will be operated by staff trained on Marken’s global procedures and managed by the inventory system, Solo. It joins Marken’s current network of depots in China, Singapore, Argentina, Mexico, Germany, and the United States.

Marken’s network of pharmaceutical depot facilities and supporting IT systems are designed to provide storage and distribution of materials for clinical trials. They are designed for all clinical materials, including temperature-controlled and time-sensitive products.

In other news, Marken has appointed Michael Culme-Seymour as vice-president, Asia Pacific Region, effective Oct. 14, 2013. Culme-Seymour will be responsible for clinical logistics and Marken’s seven branches in the region, including: Singapore, Australia, India, China, Japan, Hong Kong, and Korea. Culme-Seymour has 22 years of logistics experience with airlines, express couriers, and major post companies in Singapore, Zurich, and London.  He was most recently owner of Fischer Road Express, a private company specializing in life-science logistics. 

Source: Marken


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.